YCYoon-Mi Chung

Yoon-Mi Chung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoon-Mi Chung has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 3β-HSD1–Mediated Steroid Back-Conversion Maintains Androgen Signaling in Prostate Cancer

    by Masoud Bitaraf, Mohammad Alyamani, Nikou Fotouhi, Jinyuan Shi, Ziqi Zhu, Yoon-Mi Chung, Jennifer Freedman, Daniel J. George, Nima Sharifi

    Dihydrotestosterone (DHT), the principal driver of prostate cancer, is inactivated via reduction of its 3-keto group to a 3β-hydroxyl (3β-OH). 3β-Hydroxysteroid dehydrogenase type 1 (3β-HSD1), encoded by HSD3B1, catalyzes 3β-OH oxidation and is stabilized by an adrenal-permissive germline variant, thereby enhancing androgen biosynthesis. In this study, we tested whether 3β-HSD1 maintains androgen receptor (AR) signaling by back-converting the inactive metabolite 3β-androstanediol (3β-diol) to DHT and whether it similarly oxidizes the abiraterone (Abi) metabolite 3β-OH-5α-Abi to 3-keto-5α-Abi, a weak AR agonist. Using HSD3B1 overexpression and knockout in vitro models, we quantified steroid interconversion by mass spectrometry and AR-responsive gene expression by quantitative real-time PCR and RNA sequencing following 3β-diol exposure. HSD3B1 overexpression efficiently enabled the conversion of 3β-diol to DHT and 3β-OH-5α-Abi to 3-keto-5α-Abi. In C4-2 prostate cancer cells, 3β-diol–derived DHT regeneration and subsequent AR gene induction were blocked by the 3β-HSD1 inhibitor trilostane or abolished by HSD3B1 knockout. Clinically, in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC) treated with Abi, apalutamide, and prednisone in the PANTHER trial, men harboring the adrenal-permissive HSD3B1 genotype showed significantly greater serum depletion of 3β-OH-5α-Abi. These findings demonstrate that 3β-HSD1–mediated steroid back-conversion can maintain intratumoral androgens, providing further mechanistic insight into the poor outcomes associated with the adrenal-permissive HSD3B1 genotype and highlighting 3β-HSD1 as a critical therapeutic target in prostate cancer. Implications: 3β-HSD1–mediated back-conversion of inactivated androgens (3β-diol→DHT) and Abi metabolites (3β-OH-5α-Abi→3-keto-5α-Abi) regenerates AR-active ligands, supporting sustained AR signaling and motivating 3β-HSD1 targeting and HSD3B1 genotype–informed treatment strategies in CRPC.


  • Top Cited Papers
    Open Access

    Androgen loss accelerates brain tumour growth via HPA axis activation

    by Juyeun Lee, Yoon-Mi Chung, Daniel J. Silver, Yue Hao, Dylan Scott Lykke Harwood, Alyssa Ealy, Amanda M. Serapiglia, Lee Curtin, Julia R. Benedetti, Christine Ann Pittman Ballard, et al.

    Many cancers, including glioblastoma (GBM), show a male-biased incidence and associated worse outcomes1. The mechanisms that underlie this sex difference remain unclear but may involve an immune response2 that is partly driven by sex hormones such as androgens. Such hormones are thought to suppress antitumour T cell immunity and to promote tumour progression3,4. However, here we report a previously unreported tumour-suppressive role for androgens in brain tumours. Using mouse models, we demonstrate that androgen loss via castration accelerates intracranial tumour growth, whereas the opposite effect (delayed tumour growth) is observed in extracranial tumours. Similar effects were observed in male patients with GBM, in whom testosterone treatment significantly reduced the risk of death. In male mice with GBM tumours, castration-induced systemic T cell dysfunction driven by increased levels of serum glucocorticoids, which act on myeloid cells to promote an immunosuppressive tumour microenvironment. Mechanistically, hyperactivation of the hypothalamus-pituitary-adrenal axis in castrated mice with GBM is driven by increased neuroinflammatory signalling through IL-1β and TNF. Spatial transcriptomic analysis further revealed that androgen loss enhances inflammasome activation in microglia, which promotes this neuroinflammatory state. Together, our findings demonstrate that brain tumours drive distinct neuroinflammatory and neuroendocrine pathways in the androgen-deprived setting and highlight organ-specific regulation of antitumour immunity.


  • Open Access

    Data from Germline–Somatic Liaison Dictates Cancer Subtypes via de novo Steroid Biosynthesis

    by Paola Gasperini, Alessandro Alaimo, Blerta Stringa, Yoon-Mi Chung, Yari Ciani, Francesca Lorenzin, Giulia Fracassi, Yanis Zekri, Francesco Orlando, Orsetta Quaini, et al.

    The biological mechanisms underlying the cooperation between germline genetic variants and somatic mutations during carcinogenesis are rarely elucidated. In this study, characterizing isogenic prostate cancer cell lines, we dissected the interplay between a germline variant at the 7p14.3 locus (rs1376350, G>A) and early recurrent prostate cancer–specific mutation in the speckle-type POZ protein (SPOP) gene across human prostate adenocarcinomas. The transcriptomes of multiple edited models pointed to GLI3 and the Hedgehog signaling pathway in a genotype-specific manner, whereas SPOP mutation and androgen receptor stimulation promote GLI3 accumulation in the full-length, transcriptionally active form. This, in turn, triggers the cell-autonomous production of steroids that prostate cancer relies on, in line with the enhanced responsiveness of SPOP-mutated prostate cancer to androgen deprivation therapy. These data demonstrate that germline variants dictate prostate cancer somatic evolution and suggest opportunities to jointly model germline–somatic relationship to help untangle the complexity of human cancer.Significance:Significant heritability is observed for common cancer types worldwide. The molecular mechanisms by which inherited genetics facilitate cancer initiation might transit through its cooperation with specific somatic events that then dictate the tumor features. Through a germline–somatic tandem leading to steroid biosynthesis, we suggest a paradigm to study cancer initiation.

  • Open Access

    Supplementary Figures S1-S5 from Germline–Somatic Liaison Dictates Cancer Subtypes via de novo Steroid Biosynthesis

    by Paola Gasperini, Alessandro Alaimo, Blerta Stringa, Yoon-Mi Chung, Yari Ciani, Francesca Lorenzin, Giulia Fracassi, Yanis Zekri, Francesco Orlando, Orsetta Quaini, et al.

    The supplementary figure file includes Figures S1–S5. Descriptions of each figure are as follows: - Figure S1 shows the approach for editing the 7p14.3 locus in PC3 cells. - Figure S2 shows differential gene expression in bulk and in single clones of PC3 edited cells - Figure S3 shows the impact of single nucleotide editing on Gli3 targets Gli1 and PTCH1, and how Hh inhibitor cyclopamine prevents the accumulation of Gli3 targets. - Figure S4 shows the impact of SPOP status on CYP11A1 expression in LNCaP and 22Rv1 cells. - Figure S5 shows how SPOP status affects PR accumulation in LNCaP and PC3 cells, and how single nucleotide editing influences SRD5A1 and 3BHSD2 expression.

  • Open Access

    Supplementary Tables S1-S12 from Germline–Somatic Liaison Dictates Cancer Subtypes via de novo Steroid Biosynthesis

    by Paola Gasperini, Alessandro Alaimo, Blerta Stringa, Yoon-Mi Chung, Yari Ciani, Francesca Lorenzin, Giulia Fracassi, Yanis Zekri, Francesco Orlando, Orsetta Quaini, et al.

    The supplementary table file includes Supplementary Tables S1-S12. Descriptions of each table are as follows: - Supplementary Table 1: Study oligo sequences - Supplementary Table 2: Number of Off Targets calculated with Cas-OFFinder for the final set of guides. - Supplementary Table 3: Description of three sets of deletion editing experiements in prostate cells - Supplementary Table 4: List of study DEGs - all comparisons - Supplementary Table 5: Results of AG vs GG differential analysis (PC3 cells, single clones) - Supplementary Table 6: Results of AA vs GG differential analysis (PC3 cells, single clones) - Supplementary Table 7: Human tissue RNA-seq differential analysis for SPOPmut vs SPOPwt (AA vs AG and AG vs GG clone data DEG set) - Supplementary Table 8: GO analysis of AG vs GG DEGs - Supplementary Table 9: Sample names conversion and annotation - Supplementary Table 10: RNA sequencing statistics - Supplementary Table 11: List of antibodies used in this study - Supplementary Table 12: LC-MS/MS Steroid detection

  • Open Access

    Germline–Somatic Liaison Dictates Cancer Subtypes via de novo Steroid Biosynthesis

    by Paola Gasperini, Alessandro Alaimo, Blerta Stringa, Yoon-Mi Chung, Yari Ciani, Francesca Lorenzin, Giulia Fracassi, Yanis Zekri, Francesco Orlando, Orsetta Quaini, et al.

    The biological mechanisms underlying the cooperation between germline genetic variants and somatic mutations during carcinogenesis are rarely elucidated. In this study, characterizing isogenic prostate cancer cell lines, we dissected the interplay between a germline variant at the 7p14.3 locus (rs1376350, G>A) and early recurrent prostate cancer–specific mutation in the speckle-type POZ protein (SPOP) gene across human prostate adenocarcinomas. The transcriptomes of multiple edited models pointed to GLI3 and the Hedgehog signaling pathway in a genotype-specific manner, whereas SPOP mutation and androgen receptor stimulation promote GLI3 accumulation in the full-length, transcriptionally active form. This, in turn, triggers the cell-autonomous production of steroids that prostate cancer relies on, in line with the enhanced responsiveness of SPOP-mutated prostate cancer to androgen deprivation therapy. These data demonstrate that germline variants dictate prostate cancer somatic evolution and suggest opportunities to jointly model germline–somatic relationship to help untangle the complexity of human cancer. Significance: Significant heritability is observed for common cancer types worldwide. The molecular mechanisms by which inherited genetics facilitate cancer initiation might transit through its cooperation with specific somatic events that then dictate the tumor features. Through a germline–somatic tandem leading to steroid biosynthesis, we suggest a paradigm to study cancer initiation.


  • Open Access

    Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation

    by Di Cui, Jianneng Li, Ziqi Zhu, Michael Berk, Aimalie Hardaway, Jeffrey McManus, Yoon-Mi Chung, Mohammad Alyamani, Shelley Valle, Ritika Tiwari, et al.

    After androgen deprivation, prostate cancer frequently becomes castration resistant (CRPC), with intratumoral androgen production from extragonadal precursors that activate the androgen receptor pathway. 3β-Hydroxysteroid dehydrogenase-1 (3βHSD1) is the rate-limiting enzyme for extragonadal androgen synthesis, which together lead to CRPC. Here, we show that cancer-associated fibroblasts (CAFs) increased epithelial 3βHSD1 expression, induced androgen synthesis, activated the androgen receptor, and induced CRPC. Unbiased metabolomics revealed that CAF-secreted glucosamine specifically induced 3βHSD1. CAFs induced higher GlcNAcylation in cancer cells and elevated expression of the transcription factor Elk1, which induced higher 3βHSD1 expression and activity. Elk1 genetic ablation in cancer epithelial cells suppressed CAF-induced androgen biosynthesis in vivo. In patient samples, multiplex fluorescent imaging showed that tumor cells expressed more 3βHSD1 and Elk1 in CAF-enriched areas compared with CAF-deficient areas. Our findings suggest that CAF-secreted glucosamine increases GlcNAcylation in prostate cancer cells, promoting Elk1-induced HSD3B1 transcription, which upregulates de novo intratumoral androgen synthesis to overcome castration.


  • Open Access

    Data from Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer

    by Liang Qin, Yoon-Mi Chung, Michael Berk, Bryan Naelitz, Ziqi Zhu, Eric Klein, Abhishek A. Chakraborty, Nima Sharifi

    Androgen deprivation therapy suppresses tumor androgen receptor (AR) signaling by depleting circulating testosterone and is a mainstay treatment for advanced prostate cancer. Despite initial treatment response, castration-resistant prostate cancer nearly always develops and remains driven primarily by the androgen axis. Here we investigated how changes in oxygenation affect androgen synthesis. In prostate cancer cells, chronic hypoxia coupled to reoxygenation resulted in efficient metabolism of androgen precursors to produce androgens and activate AR. Hypoxia induced 3βHSD1, the rate-limiting androgen synthesis regulator, and reoxygenation replenished necessary cofactors, suggesting that hypoxia and reoxygenation both facilitate potent androgen synthesis. The EGLN1/VHL/HIF2α pathway induced 3βHSD1 expression through direct binding of HIF2α to the 5′ regulatory region of HSD3B1 to promote transcription. Overexpression of HIF2α facilitated prostate cancer progression, which largely depended on 3βHSD1. Inhibition of HIF2α with the small-molecule PT2399 prevented prostate cancer cell proliferation. These results thus identify HIF2α as a regulator of androgen synthesis and potential therapeutic target in prostate cancer.Significance:Hypoxia followed by reoxygenation in prostate cancer drives androgen deprivation therapy resistance via increasing the rate-limiting enzyme and cofactors for androgen synthesis, revealing HIF2α as a therapeutic target to subvert resistance.

  • Open Access

    Supplementary Data from Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer

    by Liang Qin, Yoon-Mi Chung, Michael Berk, Bryan Naelitz, Ziqi Zhu, Eric Klein, Abhishek A. Chakraborty, Nima Sharifi

    Supplementary Data from Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer